Author

Anne Ghys

Institution: Janssen (Belgium)

Observed institution: Janssen (Belgium)

OpenAlex ID: A5111596771

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

2013 · James C. Sullivan, Sandra De Meyer, et al. · Clinical Infectious Diseases · 163

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

2015 · Christoph Sarrazin, Erkki Lathouwers, et al. · Antiviral Research · 102

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

2012 · Tara L. Kieffer, Sandra De Meyer, et al. · PLoS ONE · 88

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

2012 · Sandra De Meyer, Inge Dierynck, et al. · Hepatology · 45

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study

2014 · Inge Dierynck, Kim Thys, et al. · The Journal of Infectious Diseases · 22

An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi m e HCV RNA Assay

2015 · Christoph Sarrazin, Inge Dierynck, et al. · Journal of Clinical Microbiology · 15

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

2019 · Erkki Lathouwers, Eric Y Wong, et al. · AIDS Research and Human Retroviruses · 14

Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir

2015 · Simone Susser, Mathieu Flinders, et al. · Antimicrobial Agents and Chemotherapy · 13

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment

2014 · Eric L. Haseltine, Sandra De Meyer, et al. · PLoS Computational Biology · 7

Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials

2020 · Erkki Lathouwers, Shirley Weinsteiger, et al. · Journal of Medical Virology · 4

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

2014 · Sandra De Meyer, Anne Ghys, et al. · Virology Journal · 4

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection

2014 · Gaston Picchio, Sandra De Meyer, et al. · Journal of Clinical Virology · 2

Phenotypic characterization of HCV genotype 1 protease sequences derived from patients treated with Telaprevir-based regimens in phase 3 studies

2012 · Leen Vijgen, Miaomiao Jiang, et al.

Works count: 15

Citation count: 479

H-index: 8

I10-index: 8